



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant: Elisabettni et al.
Appl. No.: 10/044,234
Conf. No.: 8974
Filed: January 11, 2002
Title: BICARBONATE-BASED SOLUTIONS FOR DIALYSIS THERAPIES
Art Unit: 1616
Examiner: F. Choi
Docket No.: DI-5782

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Sir:

In accordance with the provisions of 37 C.F.R. 1.56, 37 C.F.R. 1.97, and 37 C.F.R. 1.98, Applicants request that a citation and examination of the references cited below, and on the attached PTO-1449 form, copies of which are enclosed, be made during the course of examination of the above-identified application for United States patent.

U.S. PATENT DOCUMENTS

<u>Document No.</u>	<u>Date</u>	<u>Inventor</u>
5,211,643	05/18/93	Reinhardt et al.
5,616,248	04/01/97	Schal
6,139,754	10/31/00	Hartranft et al.

FOREIGN PATENT DOCUMENTS

<u>Document No.</u>	<u>Date</u>	<u>Country</u>
EP 0602014	06/15/94	Europe
WO 01/17534	03/15/01	PCT

12/30/2004 MBERHE 00000011 10044234

01 FC:1806

180.00 OP


All of the cited references listed above are listed in the enclosed Australian Patent Office Written Opinion dated August 3, 2004 corresponding to the present application. A copy of the Written Opinion is included with this submission.

Applicants look forward to early and favorable consideration of this matter.

Respectfully submitted,

BELL, BOYD & LLOYD LLC

BY



Robert M. Barrett


Reg. No. 30,142

P.O. Box 1135

Chicago, Illinois 60690-1135

Phone: (312) 807-4204

Date: December 21, 2004



INFORMATION DISCLOSURE CITATION IN AN APPLICATION (Use several sheets if necessary) PTO Form 1449		Atty Docket No. DI-5782	Application No. 10/044,234
		Applicant Elisabettini et al.	
		Filing Date Jan. 11, 2002	Group 1616

U.S. PATENT DOCUMENTS							
Examiner's Initials		Document Number	Publication Date	Inventor	Class	Subclass	Filing Date If Appropriate
		5,211,643	05/18/93	Reinhardt et al.			
		5,616,248	04/01/97	Schal			
		6,139,754	10/31/00	Hartranft et al.			

FOREIGN PATENT DOCUMENTS								
Examiner's Initials		Document Number	Publication Date	Country	Class	Subclass	Translation	
							Yes	No
		EP 0602014	06/15/94	Europe				
		WO 01/17534	03/15/01	PCT				


Examiner's Initials		OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

Examiner:	Date Considered:
*Examiner: Initial if citation considered, whether or not citation is in conformance with MPEP Section 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	

TRANSMITTAL OF INFORMATION DISCLOSURE STATEMENT
(Under 37 CFR 1.97(b) or 1.97(c))

Docket No.
DI-5782

In Re Application: Elisabettini et al.



Application No. 10/044,234	Filing Date January 11, 2002	Examiner F. Choi	Customer No. 29200	Group Art Unit 1616	Confirmation No. 8974
-------------------------------	---------------------------------	---------------------	-----------------------	------------------------	--------------------------

Title: **BICARBONATE-BASED SOLUTIONS FOR DIALYSIS THERAPIES**

Payment of Fee

(Only complete if Applicant elects to pay the fee set forth in 37 CFR 1.17(p))

- ☒ A check in the amount of \$180.00 is attached.
- ☒ The Director is hereby authorized to charge and credit Deposit Account No. 02-1818 as described below.
- ☐ Charge the amount of
- ☒ Credit any overpayment.
- ☒ Charge any additional fee required.
- ☐ Payment by credit card. Form PTO-2038 is attached.

WARNING: Information on this form may become public. Credit card information should not be included on this form. Provide credit card information and authorization on PTO-2038.

Certificate of Transmission by Facsimile*

I certify that this document and authorization to charge deposit account is being facsimile transmitted to the United States Patent and Trademark Office (Fax. No.
_____ (Date)
_____ Signature
_____ Typed or Printed Name of Person Signing Certificate

Certificate of Mailing by First Class Mail

I hereby certify that this correspondence is being deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to "Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450" [37 CFR 1.8(a)] on
12-21-2004 (Date)
_____ Signature of Person Mailing Correspondence
Renee Street
_____ Typed or Printed Name of Person Mailing Certificate

*This certificate may only be used if paying by deposit account.

Dated: December 21, 2004

Signature


Robert M. Barrett
Reg. No. 30,142
BELL, BOYD & LLOYD LLC
P.O. Box 1135
Chicago, IL 60690-1135
Phone: 312-807-4204

CC:

TRANSMITTAL OF INFORMATION DISCLOSURE STATEMENT
(Under 37 CFR 1.97(b) or 1.97(c))

Docket No.
DI-5782

In Re Application Of: Elisabettini et al.



Application No.	Filing Date	Examiner	Customer No.	Group Art Unit	Confirmation No.
10/044,234	January 11, 2002	F. Choi	29200	1616	8974

Title: **BICARBONATE-BASED SOLUTIONS FOR DIALYSIS THERAPIES**

Address to:
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

37 CFR 1.97(b)

1. ☐ The Information Disclosure Statement submitted herewith is being filed within three months of the filing of a national application other than a continued prosecution application under 37 CFR 1.53(d); within three months of the date of entry of the national stage as set forth in 37 CFR 1.491 in an international application; before the mailing of a first Office Action on the merits, or before the mailing of a first Office Action after the filing of a request for continued examination under 37 CFR 1.114.

37 CFR 1.97(c)

2. ☒ The Information Disclosure Statement submitted herewith is being filed after the period specified in 37 CFR 1.97(b), provided that the Information Disclosure Statement is filed before the mailing date of a Final Action under 37 CFR 1.113, a Notice of Allowance under 37 CFR 1.311, or an Action that otherwise closes prosecution in the application, and is accompanied by one of:

☐ the statement specified in 37 CFR 1.97(e);

OR

☒ the fee set forth in 37 CFR 1.17(p).